Consensus ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-01 EDT			5-day change	1st Jan Change
17.05 ^USD	+2.03%		+2.77%	-45.54%

04-30	UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating	MT
04-23	Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada	MT

Evolution of the average Target Price on ACADIA Pharmaceuticals Inc.

Price target over the last 5 years

History of analyst recommendation changes

0f7223094e54215cc2.kbRA9BuunFs-djgHIR9U6csUXro6-BOTPGG3UZ1eb8A.3_91zHnq2TlIDlUqE1w2k4pTOPANp3fFdzTRBcQJG6zy7Cy9LP_wPgpBbQ~3d4fc695f1e911df7adba7231215541d

Analyst Recommendations on ACADIA Pharmaceuticals Inc.

UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating	04-30	MT
JPMorgan Adjusts Price Target on ACADIA Pharmaceuticals to $25 From $29, Maintains Overweight Rating	03-25	MT
UBS Adjusts ACADIA Pharmaceuticals Price Target to $33 From $35, Maintains Buy Rating	03-13	MT
Morgan Stanley Cuts Price Target on ACADIA Pharmaceuticals to $30 From $40 After Failed Study of Pimavanserin in Negative Symptoms of Schizophrenia; Overweight Kept	03-13	MT
Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $22 From $24, Maintains Hold Rating	03-12	MT
Cantor Fitzgerald Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $42, Maintains Overweight Rating	03-12	MT
Baird Adjusts Price Target on ACADIA Pharmaceuticals to $31 From $40, Maintains Outperform Rating	03-12	MT
Needham Lowers Price Target on ACADIA Pharmaceuticals to $32 From $36, Keeps Buy Rating	03-12	MT
Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $19 From $25, Maintains Perform Rating	03-12	MT
Canaccord Genuity Adjusts Price Target on ACADIA Pharmaceuticals to $33 From $40, Keeps Buy Rating	03-12	MT
JMP Securities Cuts ACADIA Pharmaceuticals Price Target to $39 From $44, Maintains Market Outperform Rating	03-12	MT
RBC Cuts Price Target on ACADIA Pharmaceuticals to $30 From $35 After Phase 3 Trial of Pimavanserin Fails to Reach Primary Endpoint; Outperform Kept	03-12	MT
Mizuho Securities Downgrades ACADIA Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $25 From $39	03-12	MT
JPMorgan Cuts Price Target on ACADIA Pharmaceuticals to $29 From $32, Maintains Overweight Rating	03-01	MT
Deutsche Bank Trims ACADIA Pharmaceuticals Price Target to $24 From $25, Maintains Hold Rating	02-28	MT
Needham Trims Price Target on ACADIA Pharmaceuticals to $36 From $37, Maintains Buy Rating	02-28	MT
Mizuho Securities Adjusts Price Target on ACADIA Pharmaceuticals to $39 From $40, Maintains Buy Rating	02-28	MT
RBC Trims Price Target on ACADIA Pharmaceuticals to $35 From $36, Keeps Outperform Rating	02-28	MT
Baird Initiates ACADIA Pharmaceuticals With Outperform Rating, Price Target is $40	01-30	MT
Needham Upgrades ACADIA Pharmaceuticals to Buy From Hold, Price Target is $37	01-24	MT
RBC Boosts Price Target on ACADIA Pharmaceuticals to $36 From $33, Keeps Outperform Rating	01-03	MT
Mizuho Securities Boosts Price Target on ACADIA Pharmaceuticals to $40 From $35, Keeps Buy Rating	12-29	MT
Morgan Stanley Upgrades ACADIA Pharmaceuticals to Overweight From Equalweight, Raises Price Target to $40 From $31	12-19	MT
Stifel Adjusts Price Target on ACADIA Pharmaceuticals to $27 From $25, Maintains Hold Rating	12-18	MT
Deutsche Bank Downgrades ACADIA Pharmaceuticals to Hold From Buy, Retains $25 PT; Says Reaction to Favorable Summary Judgement on Pimavanserin's ANDA Litigation 'Slightly Overdone'	12-14	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

17.05 USD

Average target price

28.79 USD

Spread / Average Target

+68.88%

High Price Target

39 USD

Spread / Highest target

+128.74%

Low Price Target

13 USD

Spread / Lowest Target

-23.75%

Consensus detail

Consensus revision (last 18 months)

Analysts covering ACADIA Pharmaceuticals Inc.

UBS
JPMorgan Chase
Morgan Stanley
Deutsche Bank Securities
Cantor Fitzgerald
Baird
Needham & Co.
Oppenheimer
Canaccord Genuity
JMP Securities
RBC Capital Markets
Mizuho Securities
Stifel Nicolaus
Citigroup
HC Wainwright
BofA Securities
Guggenheim
Goldman Sachs
Loop Capital
SVB Securities LLC
Cowen
Jefferies & Co.
Berenberg Bank
SMBC Nikko
SVB Leerink
Raymond James

Ratings for ACADIA Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar